AZN logo

AstraZeneca PLC (AZN) Cash From Financing

Annual CFF:

-$4.00B+$2.57B(+39.15%)
December 31, 2024

Summary

  • As of today, AZN annual cash from financing is -$4.00 billion, with the most recent change of +$2.57 billion (+39.15%) on December 31, 2024.
  • During the last 3 years, AZN annual cash from financing has fallen by -$7.64 billion (-209.51%).
  • AZN annual cash from financing is now -166.04% below its all-time high of $6.05 billion, reached on December 31, 2007.

Performance

AZN Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNcash flow metrics

Quarterly CFF:

$501.20M+$3.21B(+118.52%)
June 30, 2025

Summary

  • As of today, AZN quarterly cash from financing is $501.20 million, with the most recent change of +$3.21 billion (+118.52%) on June 30, 2025.
  • Over the past year, AZN quarterly cash from financing has increased by +$1.72 billion (+141.01%).
  • AZN quarterly cash from financing is now -95.90% below its all-time high of $12.23 billion, reached on June 30, 2007.

Performance

AZN Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNcash flow metrics

TTM CFF:

-$7.01B+$1.72B(+19.74%)
June 30, 2025

Summary

  • As of today, AZN TTM cash from financing is -$7.01 billion, with the most recent change of +$1.72 billion (+19.74%) on June 30, 2025.
  • Over the past year, AZN TTM cash from financing has dropped by -$4.80 billion (-216.95%).
  • AZN TTM cash from financing is now -203.24% below its all-time high of $6.79 billion, reached on March 31, 2008.

Performance

AZN TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherAZNcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

AZN Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+39.1%+141.0%-216.9%
3Y3 Years-209.5%+138.7%-20.9%
5Y5 Years-126.4%-55.5%-10000.0%

AZN Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-209.5%+41.4%-75.3%+112.1%-216.9%+19.7%
5Y5-Year-209.5%+41.4%-93.1%+112.1%-284.5%+19.7%
All-TimeAll-Time-166.0%+57.1%-95.9%+112.1%-203.2%+26.7%

AZN Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
$501.20M(+118.5%)
-$7.01B(+19.7%)
Mar 2025
-
-$2.71B(-303.4%)
-$8.73B(-118.5%)
Dec 2024
-$4.00B(+39.2%)
-$671.00M(+83.8%)
-$4.00B(-10.5%)
Sep 2024
-
-$4.13B(-238.1%)
-$3.62B(-63.5%)
Jun 2024
-
-$1.22B(-160.3%)
-$2.21B(+11.8%)
Mar 2024
-
$2.03B(+796.9%)
-$2.51B(+61.8%)
Dec 2023
-$6.57B(+3.8%)
-$291.00M(+89.3%)
-$6.57B(+1.0%)
Sep 2023
-
-$2.73B(-79.5%)
-$6.63B(-24.3%)
Jun 2023
-
-$1.52B(+25.2%)
-$5.34B(-4.4%)
Mar 2023
-
-$2.03B(-467.3%)
-$5.11B(+25.0%)
Dec 2022
-$6.82B(-287.0%)
-$358.00M(+75.0%)
-$6.82B(+7.4%)
Sep 2022
-
-$1.43B(-10.4%)
-$7.37B(-27.1%)
Jun 2022
-
-$1.29B(+65.4%)
-$5.79B(-307.8%)
Mar 2022
-
-$3.74B(-314.6%)
$2.79B(-26.6%)
Dec 2021
$3.65B(+265.6%)
-$902.00M(-735.2%)
$3.80B(+52.5%)
Sep 2021
-
$142.00M(-98.1%)
$2.49B(-30.7%)
Jun 2021
-
$7.29B(+366.9%)
$3.59B(+239.6%)
Mar 2021
-
-$2.73B(-23.6%)
-$2.57B(-16.7%)
Dec 2020
-$2.20B(-24.8%)
-$2.21B(-277.8%)
-$2.20B(>-9900.0%)
Sep 2020
-
$1.24B(+10.4%)
$13.00M(+100.3%)
Jun 2020
-
$1.13B(+147.7%)
-$3.94B(-15.0%)
Mar 2020
-
-$2.36B(>-9900.0%)
-$3.43B(-94.3%)
Dec 2019
-$1.76B(+13.6%)
$6.00M(+100.2%)
-$1.76B(+49.6%)
Sep 2019
-
-$2.71B(-265.5%)
-$3.50B(-463.2%)
Jun 2019
-
$1.64B(+334.8%)
-$622.00M(+70.1%)
Mar 2019
-
-$698.00M(+59.7%)
-$2.08B(-1.7%)
Dec 2018
-$2.04B(+30.4%)
-$1.73B(-1124.9%)
-$2.04B(-530.9%)
Sep 2018
-
$169.00M(-7.1%)
-$324.00M(+90.9%)
Jun 2018
-
$182.00M(+127.5%)
-$3.56B(-128.8%)
Mar 2018
-
-$663.00M(-5425.0%)
-$1.56B(+47.0%)
Dec 2017
-$2.94B(-121.8%)
-$12.00M(+99.6%)
-$2.94B(+9.0%)
Sep 2017
-
-$3.07B(-240.3%)
-$3.23B(-175.4%)
Jun 2017
-
$2.19B(+207.1%)
-$1.17B(+41.5%)
Mar 2017
-
-$2.04B(-571.7%)
-$2.00B(-51.4%)
Dec 2016
-$1.32B(-250.8%)
-$304.00M(+70.0%)
-$1.32B(-140.6%)
Sep 2016
-
-$1.01B(-174.8%)
$3.26B(+0.1%)
Jun 2016
-
$1.35B(+199.6%)
$3.26B(+56.3%)
Mar 2016
-
-$1.36B(-131.8%)
$2.09B(+137.6%)
Dec 2015
$878.00M(+132.5%)
$4.28B(+520.8%)
$878.00M(+138.9%)
Sep 2015
-
-$1.02B(-662.4%)
-$2.25B(+10.6%)
Jun 2015
-
$181.00M(+107.0%)
-$2.52B(+17.6%)
Mar 2015
-
-$2.57B(-323.2%)
-$3.06B(-13.2%)
Dec 2014
-$2.71B(+11.2%)
$1.15B(+189.5%)
-$2.70B(+26.3%)
Sep 2014
-
-$1.29B(-259.2%)
-$3.67B(-4.8%)
Jun 2014
-
-$358.00M(+83.8%)
-$3.50B(-14.6%)
Mar 2014
-
-$2.21B(-1280.8%)
-$3.06B(-0.8%)
Dec 2013
-$3.05B(+38.1%)
$187.33M(+116.8%)
-$3.03B(+19.6%)
Sep 2013
-
-$1.12B(-1379.0%)
-$3.77B(-29.9%)
Jun 2013
-
$87.43M(+104.0%)
-$2.90B(+22.5%)
Mar 2013
-
-$2.19B(-298.1%)
-$3.75B(+23.9%)
Dec 2012
-$4.92B(+47.2%)
-$549.78M(-119.2%)
-$4.92B(+18.2%)
Sep 2012
-
-$250.85M(+66.9%)
-$6.02B(+29.7%)
Jun 2012
-
-$757.14M(+77.5%)
-$8.56B(+2.1%)
Mar 2012
-
-$3.37B(-105.0%)
-$8.75B(+6.0%)
Dec 2011
-$9.32B
-$1.64B(+41.3%)
-$9.31B(+2.6%)
Sep 2011
-
-$2.80B(-196.9%)
-$9.56B(-11.2%)
DateAnnualQuarterlyTTM
Jun 2011
-
-$942.00M(+76.0%)
-$8.60B(-5.9%)
Mar 2011
-
-$3.93B(-107.4%)
-$8.12B(-12.2%)
Dec 2010
-$7.33B(-102.1%)
-$1.89B(-3.3%)
-$7.23B(-34.9%)
Sep 2010
-
-$1.83B(-296.7%)
-$5.36B(-8.8%)
Jun 2010
-
-$462.35M(+84.8%)
-$4.93B(-7.1%)
Mar 2010
-
-$3.04B(>-9900.0%)
-$4.60B(-25.1%)
Dec 2009
-$3.63B(+43.0%)
-$24.03M(+98.3%)
-$3.68B(+30.2%)
Sep 2009
-
-$1.40B(-933.2%)
-$5.27B(+12.7%)
Jun 2009
-
-$135.74M(+93.6%)
-$6.04B(+1.3%)
Mar 2009
-
-$2.12B(-31.1%)
-$6.12B(+4.3%)
Dec 2008
-$6.36B(-205.1%)
-$1.62B(+25.6%)
-$6.39B(-30.1%)
Sep 2008
-
-$2.17B(-922.5%)
-$4.92B(+13.0%)
Jun 2008
-
-$212.40M(+91.1%)
-$5.65B(-183.3%)
Mar 2008
-
-$2.39B(-1648.1%)
$6.79B(+11.7%)
Dec 2007
$6.05B(+212.8%)
-$137.00M(+95.3%)
$6.08B(+19.2%)
Sep 2007
-
-$2.91B(-123.8%)
$5.10B(-16.4%)
Jun 2007
-
$12.23B(+493.7%)
$6.10B(+189.6%)
Mar 2007
-
-$3.11B(-178.8%)
-$6.81B(-27.5%)
Dec 2006
-$5.37B(-17.4%)
-$1.11B(+41.7%)
-$5.34B(-5.9%)
Sep 2006
-
-$1.91B(-182.7%)
-$5.04B(-7.0%)
Jun 2006
-
-$675.60M(+58.7%)
-$4.71B(-0.7%)
Mar 2006
-
-$1.64B(-100.8%)
-$4.67B(-1.0%)
Dec 2005
-$4.57B(-65.6%)
-$814.78M(+48.5%)
-$4.63B(-4.0%)
Sep 2005
-
-$1.58B(-146.6%)
-$4.45B(-14.3%)
Jun 2005
-
-$641.58M(+59.6%)
-$3.89B(-4.1%)
Mar 2005
-
-$1.59B(-149.5%)
-$3.74B(-34.8%)
Dec 2004
-$2.76B(-3.3%)
-$637.24M(+37.8%)
-$2.77B(+20.6%)
Sep 2004
-
-$1.02B(-110.0%)
-$3.49B(-54.7%)
Jun 2004
-
-$487.39M(+22.0%)
-$2.26B(+28.9%)
Mar 2004
-
-$624.64M(+54.0%)
-$3.18B(-18.3%)
Dec 2003
-$2.67B(+19.3%)
-$1.36B(-740.8%)
-$2.69B(-24.4%)
Sep 2003
-
$212.00M(+115.1%)
-$2.16B(+10.9%)
Jun 2003
-
-$1.41B(-957.1%)
-$2.42B(+3.5%)
Mar 2003
-
-$132.96M(+84.0%)
-$2.51B(+0.1%)
Dec 2002
-$3.31B(-71.2%)
-$832.53M(-1534.8%)
-$2.51B(-14.4%)
Sep 2002
-
-$50.92M(+96.6%)
-$2.20B(+22.2%)
Jun 2002
-
-$1.49B(-1007.1%)
-$2.82B(-8.1%)
Mar 2002
-
-$135.00M(+73.9%)
-$2.61B(+1.2%)
Dec 2001
-$1.94B(-383.4%)
-$516.96M(+23.7%)
-$2.64B(-20.8%)
Sep 2001
-
-$677.24M(+47.2%)
-$2.19B(-38.8%)
Jun 2001
-
-$1.28B(-665.9%)
-$1.58B(-276.3%)
Mar 2001
-
-$167.46M(-174.9%)
-$418.93M(-4.7%)
Dec 2000
-$400.29M(+75.8%)
-$60.91M(+6.8%)
-$400.29M(-17.9%)
Sep 2000
-
-$65.34M(+47.8%)
-$339.38M(-23.8%)
Jun 2000
-
-$125.23M(+15.8%)
-$274.04M(-84.2%)
Mar 2000
-
-$148.81M
-$148.81M
Dec 1999
-$1.65B(-631.0%)
-
-
Dec 1998
-$226.00M(-327.2%)
-
-
Dec 1997
-$52.90M(+20.8%)
-
-
Dec 1996
-$66.79M(-190.0%)
-
-
Dec 1995
$74.17M(+109.2%)
-
-
Dec 1994
-$805.15M(-219.9%)
-
-
Dec 1993
$671.56M(+638.0%)
-
-
Dec 1992
$91.00M(+134.7%)
-
-
Dec 1991
-$261.97M(+52.8%)
-
-
Dec 1990
-$555.53M
-
-

FAQ

  • What is AstraZeneca PLC annual cash from financing?
  • What is the all-time high annual cash from financing for AstraZeneca PLC?
  • What is AstraZeneca PLC annual cash from financing year-on-year change?
  • What is AstraZeneca PLC quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for AstraZeneca PLC?
  • What is AstraZeneca PLC quarterly cash from financing year-on-year change?
  • What is AstraZeneca PLC TTM cash from financing?
  • What is the all-time high TTM cash from financing for AstraZeneca PLC?
  • What is AstraZeneca PLC TTM cash from financing year-on-year change?

What is AstraZeneca PLC annual cash from financing?

The current annual cash from financing of AZN is -$4.00B

What is the all-time high annual cash from financing for AstraZeneca PLC?

AstraZeneca PLC all-time high annual cash from financing is $6.05B

What is AstraZeneca PLC annual cash from financing year-on-year change?

Over the past year, AZN annual cash from financing has changed by +$2.57B (+39.15%)

What is AstraZeneca PLC quarterly cash from financing?

The current quarterly cash from financing of AZN is $501.20M

What is the all-time high quarterly cash from financing for AstraZeneca PLC?

AstraZeneca PLC all-time high quarterly cash from financing is $12.23B

What is AstraZeneca PLC quarterly cash from financing year-on-year change?

Over the past year, AZN quarterly cash from financing has changed by +$1.72B (+141.01%)

What is AstraZeneca PLC TTM cash from financing?

The current TTM cash from financing of AZN is -$7.01B

What is the all-time high TTM cash from financing for AstraZeneca PLC?

AstraZeneca PLC all-time high TTM cash from financing is $6.79B

What is AstraZeneca PLC TTM cash from financing year-on-year change?

Over the past year, AZN TTM cash from financing has changed by -$4.80B (-216.95%)
On this page